We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 25, 2019

BRAF Fusions Are an Emerging Therapeutic Biomarker in Melanoma Patients

Journal of Clinical Pathology


Additional Info

Journal of Clinical Pathology
Testing for BRAF Fusions in Patients With Advanced BRAF/NRAS/KIT Wild-Type Melanomas Permits to Identify Patients Who Could Benefit of Anti-MEK Targeted Therapy
J. Clin. Pathol. 2019 Sep 10;[EPub Ahead of Print], G Le Flahec, M Briolais, B Guibourg, G Lemasson, JL Grippari, F Ledé, P Marcorelles, A Uguen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading